1-3 of 3
Cheryl A. Eaton, BA
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

NKTT120 Reduces iNKT Cells without Dose Limiting Toxicity in Stable Adult Sickle Cell Patients in a Phase 1 Trial

Elaine M. Majerus, MD PhD, Kenneth I. Ataga, MD, Elliott Vichinsky, MD, Cheryl A. Eaton, BA, Rosemary Mazanet, MD PhD, David G. Nathan, MD, Joshua J. Field, MD MS
Journal: Blood
Blood (2014) 124 (21): 2718.
https://doi.org/10.1182/blood.V124.21.2718.2718
Published: 2014
Journal Articles

Adult Patients with Stable Sickle Cell Disease Prior to Treatment with the iNKT Cell Depleting Antibody NKTT120 Have Consistent and Elevated Numbers of Activated (CD69 + ) iNKT Cells Relative to Healthy Adult Volunteers

Rosemary Mazanet, MD PhD, Robert Schaub, PhD, Felix Scheuplein, PhD, Cheryl A. Eaton, BA, Robert Mashal, MD, Joshua J. Field, MD MS
Journal: Blood
Blood (2014) 124 (21): 4097.
https://doi.org/10.1182/blood.V124.21.4097.4097
Published: 2014
Journal Articles

A Phase I Single Ascending Dose Study Of NKTT120 In Stable Adult Sickle Cell Patients

Joshua J. Field, MD, MS, Kenneth I. Ataga, MD, Elaine Majerus, MD, PhD, Cheryl A. Eaton, BA, Robert Mashal, MD, David G. Nathan, MD
Journal: Blood
Blood (2013) 122 (21): 977.
https://doi.org/10.1182/blood.V122.21.977.977
Published: 2013